Pathogenesis of primary hepatocellular carcinoma

European Journal of Gastroenterology and Hepatology

Volumn 8, Issue 9, 1996, Pages 850-855

  Curry, Graham W ^a   Beattie, Alistair D ^a  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Aflotoxins; Chronic liver disease; Growth factors; HBV; HCV; Hepatocellular carcinoma; Oncogene

Indexed keywords

ESTROGEN; SEX HORMONE;

CARCINOGENESIS; CELL GROWTH; CHRONIC LIVER DISEASE; GROWTH REGULATION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY;

AFLATOXINS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; CHRONIC DISEASE; ENDOCRINE SYSTEM DISEASES; ESTROGENS; GONADAL STEROID HORMONES; HEPATITIS B; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS;

EID: 0029737852     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (120)

1. Aflatoxins. IARC Monogr Eval Carcinog Risks Hum 1993, 56:245-395.
2. Busby WF, Jt, Wogan GN: Aflatoxins. In Chemical Carcinogens, 2nd Edn, Vol. 2. Edited by Searle CE. Washington: American Chemical Society; 1984:945-1136.
3. Newberne PM, Butler WH: Acute and chronic effects of aflatoxin on the liver of domestic and laboratory animals: a review. Cancer Res 1969, 29:236-250.
4. Groopman JD, Cain LG, Kensler TW: Aflatoxin exposure in human populations: measurements and relationship to cancer. CRC Crit Rev Toxicol 1988, 19:113-145.
5. Diallo MS, Sylla A, Sidibe K, Sylla BS, Trepo CR, Wild CP: Prevalence of exposure to aflatoxin and hepatitis B and C viruses in Guinea, West Africa. Nat Toxins 1995, 3(1):6-9.
6. Olubuyide IO, Maxwell SM, Hood H, Neal GE, Hendrickse RG: HBsAg, aflatoxins and primary hepatocellular carcinoma. Afr J Med Med Sci 1993, 22(3):89-91.
7. Watt JJ, Vincent TJ, Purchase IF: Hepatocellular carcinoma and dietary aflatoxin in Mozambique and Transkei. Br J Cancer 1985, 51:713-722.
8. Peers F, Bosch X, Kaldor J, Linsell A, Pluijmen M: Aflatoxin exposure, hepatitis B virus infection and liver cancer in Swaziland. Int J Cancer 1987, 39:545-553.
9. Wogan GN: Aflatoxins as risk factors for hepatocellular carcinoma. Cancer Res 52(suppl.):2114s-2118s.
10. McGlynn KA, Rosvold EA, Lustbader ED, Hu Y, Clapper ML, Zhou T, et al.: Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc Natl Acad Sci USA 1995, 14:2384-2387.
11. Slagle BL: p53 mutations and hepatitis B virus: cofactors in hepatocellular carcinoma. Hepatology 1995, 21:597-599.
12. Smuzness W: Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal relationship. Prog Med Virol 1978, 24:40-69.
13. Hadziyannis SJ: Hepatocellular carcinoma and type B hepatitis. Clin Gastroenterol 1980, 9:117-134.
14. Harris CC, Sun TT: Interactive effects of carcinogens and hepatitis B virus in the pathogenesis of hepatocellular carcinoma. Cancer Surv 1986, 5:765-780.
15. Yeh FS, Yu MC, Mo CC, Luo S, Tong MJ, Henderson, BJ: Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China. Cancer Res 1989, 49:2506-2509.
16. Yeh FS, Yu MC, Mo CC, Luo S, Tong MJ, Henderson BJ, et al: A serological case control study of primary hepatocellular carcinoma in Guangxi, China. Cancer Res 1985, 45:872-873.
17. Kew MC, Desmyter J, Bradburne AF, Macnab GM: Hepatitis B virus infections in southern African blacks with hepatocellular carcinoma. J Natl Cancer Inst 1979, 62:517-520.
18. Lau JYN, Lai CL: Hepatocarcinogenesis. Trop Gastroenterol 1990, 11:9-24.
19. Summers J: Three recently described animal virus models for human hepatitis B virus. Hepatology 1981, 1:179-183.
20. Popper H, Roth L, Purcell RH, Tennant BC, Gerin JL: Hepatocarcinogenicity of the woodchuck hepatitis virus. Proc Natl Acad Sci USA 1987, 84:886-890.
21. Huang SN, Chisari FV: Strong, sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice. Hepatology 1995, 21:620-626.
22. Kirby GM, Chemin I, Montesano R, Chisari FV, Lang MA, Wild CP: Induction of specific cytochrome P450s involved in aflatoxin B1 metabolism in hepatitis B virus transgenic mice. Mol Carcinog 1994, 11(2):74-80.
23. Toshkov I, Chisari FV, Bannasch P: Hepatic preneoplasia in hepatitis B virus transgenic mice. Hepatology 1994, 20:1162-1172.
24. Kim C-M, Koike R, Saito I, Miyamura T, Jay G: HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991, 351:317-320.
25. Shafritz DA, Shouval D, Sherrnan HI, Hadziyannis SJ, Kew MC: Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med 1981, 305:1067-1073.
26. Paterlini P, Poussin K, Kew M, Franco D, Brechot C: Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology 1995, 21:313-321.
27. Shafritz DA, Kew MC: Identification of integrated hepatitis B virus DNA sequences in human hepatocellular carcinomas. Hepatology 1981, 1:1-3.
28. Yaginuma H, Kobayashi H, Kobayashi M, et al.: Multiple integration site of hepatitis B virus DNA in hepatocellular carcinoma and chronic active hepatitis tissues from children. J Virol 1987, 61:1808-1813.
29. Slagle BL, Zhou YZ, Butel JS: Hepatitis B virus integration event in human chromosome 17p near the p53 gene identifies the region of the chromosome commonly deleted in virus-positive hepatocellular carcinoma. Cancer Res 1991, 51:49-54.
30. Fisher JH, Scoggin CH, Rogler CE: Sequences which flank an lip deletion observed in an hepatocellular carcinoma map to 11p13. Hum Genet 1987, 75:66-69.
31. Lee HS, Rajagopalan MS, Vyas GN: A lack of direct role of hepatitis B virus in the activation of ras and c-myc oncogenes in human hepatocellular carcinogenesis. Hepatology 1988, 8:1116-1120.
32. Pasquinelli C, Bhavani K, Chisari FV: Multiple oncogenes and tumor suppressor genes are structurally and functionally intact during hepatocarcinogenesis in hepatitis B virus transgenic mice. Cancer Res 1992, 52:2823-2829.
33. Spandau DF, Lee CH: Trans-activation of viral enhancers by the hepatitis B virus X protein. J Virol 1988, 62:427-434.
34. Twu JS, Schloemer RH: Transcriptional trans-activating function of hepatitis B virus. J Virol 1987, 61:3448-3453.
35. Wollersheim M, Delbelka U, Hofschneider PH: A trans-activating function encoded in the hepatitis B virus X gene is conserved in the integrated state. Oncogene 1988, 3:545-522.
36. Kekule AS, Lauer U, Meyer M, Caselman VH, Hofschneider PH, Koshy R: The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator. Nature 1990, 343:457-461.
37. Caselmann WH, Meyer M, Kekule AS, Lauer U, Hofschneider PH, Koshy R: A trans-activator function is generated by integration of hepatitis B virus preS/S sequences in human hepatocellular carcinoma DNA. Proc Natl Acad Sci USA 1990, 87:2970-2974.
38. Briux J, Barrera JM, Calvet X, Ercilla G, Costa J, Sanchez-Tapias JM, et al.: Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989, ii:1004-1006.
39. Nishioka K, Watanabe J, Furuta S, Tanaka E, Iino S, Suzuki H. et al.: A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer 1991, 67:429-433.
40. Baur M, Hay U, Novaceck G, Dittrich C, Ferenci P: Prevalence of antibodies to hepatitis C virus in patients with hepatocellular carcinoma in Austria. Arch Virol 1992, 4(suppl.):76-80.
41. Mangia A, Vallari D, Di Bisceglie AM: Use of confirmatory tests for hepatitis C viral infection in patients with hepatocellular carcinoma. J Med Virol 1994, 43:125-128.
42. Bukh J, Miller RH, Kew MC, Purcell RH: Hepatitis C virus RNA in southern African blacks with hepatocellular carcinoma. Proc Natl Acad Sci USA 1993, 90:1848-1851.
43. Chou WH, Yoneyama T, Takeuchi K, Harada H, Saito J, Miyamura T: Discrimination of hepatitis C virus in liver tissues from different patients with hepatocellular carcinomas by direct nucleotide sequencing of amplified cDNA of the viral genome. J Clin Microbiol 1991, 29:2860-2864.
44. Haruna Y, Hayashi N, Takenobu K, Hytiroglou P, Thung SN, Gerber MA: Expression of hepatitis C virus in hepatocellular carcinoma. Cancer 1994, 73:2253-2258.
45. Horiike N, Nonaka T, Kumamoto I, Kajino K, Onji M, Ohta Y: Hepatitis C virus plus- and minus-strand RNA in hepatocellular carcinoma and adjoining nontumorous liver. J Med Virol 1993, 41:312-315.
46. Choo QL, Kuo G, Weiner AJ, et al.: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244:359-362.
47. Gilliam JH III, Geinsenger KR, Richter JE: Primary hepatocellular carcinoma after chronic non-A, non-B post transfusion hepatitis. Ann Intern Med 1984, 101:794-795.
48. Kiyosawa K, Akahane Y, Nagata A, Furuta S: Hepatocellular carcinoma after non-A, non-B posttransfusion hepatitis. Am J Gastroenterol 1984, 79:777-781.
49. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, et al.: Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990, 12:671-675.
50. Yu MW, Chen CJ: Hepatitis B and C viruses in the development of hepatocellular carcinoma. Crit Rev Oncol Hematol 1994, 17(2):71-91.
51. Yu MW, You SL, Chang AS, Lu SN, Liaw YF, Chen CJ: Association between hepatitis C virus antibodies and hepatocellular carcinoma in Taiwan. Cancer Res 1991, 51:5621-5625.
52. Kew MC, Houghton M, Choo QL, Kuo G: Hepatitis C virus antibodies in Southern African blacks with hepatocellular carcinoma. Lancet 1990, 335:873-874.
53. Okuno H, Xie ZC, Lu BY, Qin X, Takasu M, Kano H, et al.: A low prevalence of anti-hepatitis C virus antibody in patients with hepatocellular carcinoma in Guangxi Province, Southern China. Cancer 1994, 73(1):58-62.
54. Srivatanakul P, Parkin DM, Khlat M, Chenvidhya D, Chotiwan P, Insiripong S, et al.: Liver cancer in Thailand: II. A case control study of hepatocellular carcinoma, Int J Cancer 1991, 48:329-332.
55. Yu MW, Chen CJ: Elevated serum testerone levels and risk of hepatocellular carcinoma. Cancer Res 1993, 53:790-794.
56. Johnson PJ, Williams R: Hepatitis C antibodies and hepatocellular carcinoma: new clues or false trail? J Natl Cancer Inst 1990, 82:9860-9987.
57. Aach RD, Stevens CE, Hollinger FB, Mosley JW, Peterson DA, Taylor PE, et al.: Hepatitis C virus infection in post-transfusion hepatitis: an analysis with first- and second-generation assays N Engl J Med 1991, 325:1325-1329.
58. Houghton M, Weiner A, Han J, Juo G, Choo QL: Molecular biology of the hepatitis C viruses: implications for the diagnosis, development and control of viral disease. Hepatology 1991, 14:381-388.
59. Kim DW, Suzuki R, Harada T, Saito I, Miyamura T: Trans-suppression of gene expression by hepatitis C viral core protein. Jap J Med Sci and Biol 1994, 47:211-220.
60. Herr W, Gerken G, Poralla T, Immenschuh S, Schirmacher P, Steepmuller KW, et al.: Hepatitis C associated hepatocellular carcinoma in a noncirrhotic liver. Clin Invest 1993, 71:49-53.
61. De Mitri MS, Poussin K, Baccarini P, Pontisso P, D'Errico A, Simon N, et al.: HCV-associated liver cancer without cirrhosis. Lancet 1995, 345:413-415.
62. Kato N, Yokosuka O, Hosoda K,Ito Y, Ohto M, Omata M: Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: increase of the virus in advanced liver disease. Hepatology 1993, 18:16-20.
63. Lefkowitch JH, Apfelbaum TF: Liver cell dysplasia and hepatocellular carcinoma in non-A, non-B hepatitis. Arch Pathol Lab Med 1987, 111:170-173.
64. Anthony PP, Vogel CL, Barker LF: Liver cell dysplasia: a pre-malignant condition. J Clin Pathol 1973, 26:217-223.
65. Villa E, Camellini L, Dugani A, Zutcchi F, Grottola A, Merighi A, et al.: Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma. Cancer Res 1995, 55:498-500.
66. Blanck A, Liao D, Gustafsson JA, Hallstrom IP: Hormonal regulation of sex differentiated parameters in liver nodules from rats treated in the resistant hepatocyte model Carcinogenesis 1995, 16:231-235.
67. Farinati F, De Maria N, Marafin C, Fagiuoli S, Libera GD, Naccarato R: Hepatocellular carcinoma in alcoholic cirrhosis: is sex hormone imbalance a pathogenetic factor? Eur J Gastroenterol Hepatol 1995, 7:145-150.
68. International Agency for Research on Cancer: Alcohol drinking. IARC Monogr Eval Carcinog Risks Hum 1988,44: 207-215.
69. Fischer G, Hartmann H, Droese M, et al.: Histochemical and immunohistochemical detection of putative preneoplastic liver foci in women after long-term use of oral contraceptives. Virchows Archiv Abteilung B Cell Pathology 1986, 50:321-337.
70. Neuberger J, Portmann B, Nunnerly HB, Laws JW, Davis M, Williams R: Oral-contraceptive-associated liver tumours: occurrence of malignancy and difficulties in diagnosis. Lancet 1980, i:273-276.
71. Gyorffy EJ, Bredfeldt JR, Black WC: Transformation of hepatocellular adenoma to hepatocellular carcinoma due to oral contraceptive use. Arch Intern Med 1989, 110:489-490.
72. Sheu JC, Sung JL, Chen DS, et al.: Early detection of hepatocellular carcinoma by real-time ultrasonography. A prospective study. Cancer 1985, 56:660-666.
73. Oka H, Kurioka N, Kim K, Kanno T, Kuroki T, Mizoguchi Y, et al.: Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990, 12:680-687.
74. Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, et al.: Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991, 325:675-680.
75. Craig JR, Klatt EC, Yu M: Role of cirrhosis and the development of HCC: evidence from histologic studies and large population studies. In Etiology, Pathology, and Treatment of Hepatocellular Carcinoma in North America. Edited by Tabor E, Di Bisceglie AM, Purcell RH. The Woodlands: Portfolio Publishing; 1991.
76. Kew MC, Popper H: Relationship between hepatocellular carcinoma and cirrhosis. Semin Liver Dis 1984, 4:136-145.
77. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, et al.: Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B. Hepatology 1995, 21:77-82.
78. Propst T, Propst A, Dietze O, Judmaier G, Braunsteiner H, Vogel W: Prevalence of hepatocellular carcinoma in alpha-1-anti-trypsin deficiency. J Hepatol 1994, 21:1006-1011.
79. Salata H, Cortes JM, de Salamanca RE, et al.: Porphyria cutanea tarda and hepatocellular carcinoma. J Hepatol 1985, 1:477-487.
80. Deugnier Y, Guyader D, Crantock L, Lopez J, Turlin B, Yaouanq J, et al.: Primary liver cancer in genetic haemochromatosis: a clinical, pathological and pathogenetic study in 54 cases. Gastroenterology 1993, 104:228-234.
81. Stal P, Hultcrantz R, Moller L, Eriksson LC: The effects of dietary iron on initiation and promotion in chemical hepatocarcinogenesis. Hepatology 1995, 21:521-528.
82. Park YN, Jung WH, Park C: The effect of deferoxamine on the preneoplastic lesions in the chemically induced hepatocarcinogenesis. Yonsei Medical Journal 1994, 35:388-395.
83. Goldfarb S, Pugh TD: The origin and significance of hyper-plastic hepatocellular islands and nodules in hepatic carcinogenesis. J Am Coll Toxicol 1982, 1:119-144.
84. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991, 253:1708-1711.
85. Cerutti P, Hussain P, Pourzand C, Aguilar F: Mutagenesis of the H-ras protooncogene and the p53 tumor suppressor gene. Cancer Res 1994, 54(suppl. 7):1934s-1938s.
86. Gerbes AL, Caselmann WH: Point mutations of the p53 gene, human hepatocellular carcinoma and aflatoxins. J Hepatol 1993, 19(2):312-315.
87. Hussain SP, Aguilar F, Amstad P, Cerutti P: Oxy-radical induced mutagenesis of hotspot codons 248 and 249 of the human p53 gene. Oncogene 1994, 9(8):2277-2281.
88. Ozturk M: p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991, 338:1356-1359.
89. Li D, Cao Y, He L, Wang NJ, Gu JR: Aberrations of p53 gene in human hepatocellular carcinoma from China. Carcinogenesis 1993, 14(2):169-173.
90. Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P: Geographic variation of p53 mutational profile in nonmalignant human liver. Science 1994, 264:1317-1319.
91. Volkmann M, Hofmann WJ, Muller M, Rath U, Otto G, Zentgraf H, et al.: p53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation. Oncogene 1994, 9:195-204.
92. De Benedetti VM, Welsh JA, Trivers GE, Harpster A, Parkinson AJ, Lanier AP, et al.: p53 is not mutated in hepatocellular carcinomas from Alaska natives. Cancer Epidemiol Biomarkers Prev 1995, 4:79-82.
93. Collier JD, Carpenter M, Burt AD, Bassendine MF: Expression of mutant p53 protein in hepatocellular carcinoma. Gut 1994, 35(1):98-100.
94. Fujimoto Y, Hampton LL, Wirth PJ, Wang NJ, Xie JP, Thorgeirsson SS: Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China. Cancer Res 1994, 54:281-285.
95. Ng IO, Srivastava G, Chung LP, Tsang SW, Ng MM: Overexpression and point mutations of p53 tumor suppressor gene in hepatocellular carcinomas in Hong Kong Chinese people. Cancer 1994, 74(1):30-37.
96. Livni N, Eid A, Ilan Y, Rivkind A, Rosenmann E, Blendis IM, et al.: p53 expression in patients with cirrhosis with and without hepatocellular carcinoma. Cancer 1995, 75(10):2420-2426.
97. Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P: Geographic variation of p53 mutational profile in nonmalignant human liver. Science 1994, 264:1317-1319.
98. Kennedy SM, Macgeogh C, Jaffe R, Spurr NK: Overexpression of the oncoprotein p53 in primary hepatic tumors of childhood does not correlate with gene mutations. Hum Pathol 1994, 25(5):438-442.
99. Teramoto T, Satonaka K, Kitawaza S, Fujimori T, Hayashi K, Medea S: p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis. Cancer Res 1994, 54:231-235.
100. Buetow KH, Sheffield VC, Zhu M, Zhou T, Shen FM, Hino O, et al.: Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas. Proc Natl Acad Sci USA 1992, 89(20):9622-9626.
101. Ogata N, Kamimura T, Asakura H: Point mutation, allelic loss and increased methylation of c-Ha-ras gene in human hepatocellular carcinoma. Hepatology 1991, 13:31-37.
102. Pascale RM, Simile MM, Feo F: Genomic abnormalities in hepatocarcinogenesis. Implications for a chemopreventive strategy. Anticancer Research 1993, 13:1341-1356.
103. Gu JR, Hu LF, Cheng YC, Wan DF: Oncogenes in primary hepatic cancer. J Cell Physiol 1986, 4(suppl.):13-20.
104. Takada S, Koike K: Activated N-ras gene was found in human hepatoma tissue, but only in a small fraction of the tumour cells. Oncogene 1989, 4:189-193.
105. Pascale RM, Simile MM, Feo F: Genomic abnormalities in hepatocarcinogenesis. Implications for a chemopreventive strategy. Anticancer Research 1993, 13:1341-1356.
106. Conte D, Neri A, Fracchiolla NS, Croce LS, Lodi L, Fraquelli M, et al.: Analysis of p53 and ras gene mutations in hepatocellular carcinoma in Italy. Eur J Gastroenterol Hepatol 1994, 6:1005-1008.
107. Fang XJ, Keating A, Flowers M, Liew CC, Gupta H, Mills GB, et al.: The v-raf oncogene enhances tumorigenicity and suppresses differentiation in vivo in a rat hepatocyte cell line. Carcinogenesis 1993, 14:669-674.
108. Jou YS, Layhe B, Matesic DF, Chang CC, Pe Feijter AW, Lockwood L, et al.: Inhibition of gap functional intercellular communication and malignant transformation of rat liver epithelial cells by neu oncogene. Carcinogenesis 16:311-317.
109. Ledda-Columbano GM, Coni P, Simbula G, Zedda I, Columbano A: Compensatory regeneration, mitogen-induced liver growth, and multistage chemical carcinogenesis. Environmental Health Perspectives 1993, 101(suppl. 5):163-168.
110. Ito N, Kawata S, Tamura S, Shirai Y, Kiso S, Tsushima H, et al.: Positive correlation of plasma transforming growth factor-beta 1 levels with tumor vascularity in hepatocellular carcinoma. Cancer Letters 1995, 89:45-48.
111. Sun D, Kar S, Carr BI: Differentially expressed genes in TGF-beta 1 sensitive and resistant human hepatoma cells. Cancer Letters 1995, 89:73-79.
112. Reisenbichler H, Chari RS, Boyer IJ, Jirtle RL: Transforming growth factor beta receptors type I, II and III in phenobarbital-promoted rat liver tumors. Carcinogenesis 1994, 15:2763-2767.
113. James NH, Roberts RA: The peroxisome proliferator class of non-genotoxic hepatocarcinogens synergize with epidermal growth factor to promote clonal expansion of initiated rat hepatocytes. Carcinogenesis 1994, 15:2687-2694.
114. Nakayama N, Kashiwazaki H, Kobayashi N, Hamada LJ, Matsumoto K, Nakamura T, et al.: Differing distribution of hepatocyte growth factor-positive cells in the liver of LEC rats with acute hepatitis, chronic hepatitis and hepatoma. Jap J Cancer Res 1995, 86:5-9.
115. Grigioni WF, Fiorentino M, D'Errico A, Ponzetto A, Crepaldi T, Prat M, et al.: Overexpression of the c-met protooncogene product and raised Ki-67 index in hepatocellular carcinoma with respect to benign liver conditions. Hepatology 1995, 21:1543-1546.
116. Manifold IH, Triger DR, Underwood JCE: Kupffer-cell depletion in chronic liver disease: implications for hepatic carcinogenesis. Lancet 1983, ii:431-433.
117. Kan Z, Ivancev K, Lunderquist A, McCuskey PA, McCuskey RS, Wallace S: In vivo microscopy of hepatic metastases: dynamic observation of tumor cell invasion and interaction with Kupffer cells. Hepatology 1995, 21:487-494.
118. Yonish-Rouach E, Resnitzky J, Lotem L, Sachs A, Kimchi A, Oren M: Wildtype p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991, 352:345-357.
119. Zerban H, Radig S, Kopp-Schneider A, Bannasch P: Cell proliferation and cell death (apoptosis) in hepatic preneoplasia and neoplasia are closely related to phenotypic cellular diversity and instability. Carcinogenesis 1994, 15:2467-2473.
120. Sell S: The role of determined stem-cells in the cellular lineage of hepatocellular carcinoma. Int J Dev Biol 1993, 37(1):189-201.